Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Conditions: Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma Interventions: Drug: Anastrozole 1mg; Drug: Letrozole 2.5mg; Drug: Exemestane 25 mg; Drug: Tamoxifen Sponsor: Emily Marcinkowski Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Endocrine Therapy | HER2 | Neoadjuvant Therapy | Research | Tamoxifen